A Natural Analgesic & Anti-inflammatory for Chronic Pain Relief.

Mechanism of Action:

• Activates PPAR-α, suppressing NF-κB and pro-inflammatory cytokines
• Inhibits mast cell and microglial activation → reduces neuroinflammation
• Enhances endocannabinoid activity (CB1, CB2, TRPV1) – the “entourage effect”
• Modulates glutamate transmission and neuronal excitability
• Promotes neuroprotection and nerve regeneration

Clinical Benefits:

• Neuropathic Pain: Reduces inflammation and nerve hypersensitivity
• Diabetic Neuropathy: Decreases nerve inflammation, improves nerve conduction and reduces burning, tingling, and pain
• Fibromyalgia: Alleviates chronic widespread pain and fatigue by modulating central sensitization
• Sciatica: Reduces radicular pain and inflammation along the sciatic nerve
• Rheumatoid Arthritis: Lowers cytokine-mediated joint inflammation
• Musculoskeletal Pain: Relieves osteoarthritis and chronic muscle pain
• Migraine Prophylaxis: Helps modulate neuroinflammation and neuronal excitability, reducing migraine frequency and intensity.
• Cancer Pain: Effective adjuvant for cancer-related neuropathic pain

Key Advantages:

Multi-target pain modulation

Effective across neuropathic, inflammatory & nociceptive pain

Excellent safety and tolerability

Non-sedative & non-addictive

Ideal adjunct in chronic pain management

PALMICRON — Multi-Pathway Relief for Neuropathic, Inflammatory & Chronic Pain

CITIBLINK P is indicated for:

* Acute ischemic stroke recovery

* Neuroprotection and brain cell repair

* Cognitive enhancement post-stroke or brain injury.

It supports neuronal healing, improves cerebral circulation, and enhances memory and focus during neurological rehabilitation.

Mechanism of Action:

Citicoline:

* Boosts phosphatidylcholine synthesis for membrane repair

* Enhances acetylcholine production for cholinergic recovery

* Reduces free fatty acid accumulation at injury sites

Piracetam:

* Modulates acetylcholine receptor function

* Improves neuronal communication and synaptic plasticity

* Enhances cerebral blood and oxygen flow

Together, they act synergistically to restore neural integrity and optimize post-stroke recovery.

Clinical Advantages:

* Accelerates neurological recovery after stroke

* Enhances cognitive function and memory

* Protects neurons from hypoxic and ischemic damage

* Improves cerebral perfusion and metabolic resilience

* Well-tolerated with a favorable safety profile

CITIBLINK P — Reignite cognition. Restore clarity. Rebuild the mind.

Composition:

Mecobalamin 1500 mcg · Alpha Lipoic Acid 200 mg · Benfotiamine 150 mg · Folic Acid 1.5 mg · Chromium Picolinate 200 mcg · Inositol 100 mg · Pyridoxine 3 mg · Calcium Carbonate 500 mg · Vitamin D3 1000 IU

Key Benefits:

• Supports nerve regeneration & relieves neuropathic pain
• Enhances glucose metabolism & energy production
• Provides antioxidant protection against oxidative stress
• Strengthens bones & improves calcium absorption
• Promotes overall metabolic & nervous system health

Clinical Applications:

• Diabetic & peripheral neuropathy
• Neurodegenerative disorders
• Metabolic imbalance & fatigue
• Bone weakness & deficiency states

Benfoblink forte — Revitalize Nerves. Restore Strength. Rebalance Metabolism.

Sterile lyophilized powder containing Cerebroprotein Hydrolysate 60 mg, composed of 16 amino acids and polypeptides.

Free from proteins, lipids, and antigens—minimizing hypersensitivity risk.

Mechanism of Action:

* Mimics neurotrophic factors (NTFs) to regulate CNS development and repair

* Enhances neuronal metabolism, plasticity, and differentiation

* Protects against ischemic and neurotoxic damage

* Reduces excitotoxic injury, blocks calcium-dependent protease activation, and scavenges free radicals

* Activates Sonic Hedgehog (Shh) signaling for neurorestoration.

Key Benefits:

* Accelerates recovery in brain injuries and dementia

* Improves daily living activities and reduces caregiver dependence

* Detectable neurotrophic activity within 24 hours of dosing

* Safe, well-tolerated, and effective across neurological disorders

Indications:

* Cranial injury recovery

* Cerebrovascular sequelae

* Aprosexia in dementia

 Dosage & Administration:

* 60–180 mg daily, dissolved in 5–15 ml water for injection

* Further diluted in 250 ml normal saline

* Administered for 10–20 consecutive days, based on age and severity

Note: To be used only under the guidance of a registered medical practitioner.

COGNICRON — Rebuild the brain. Restore the life.

Amitriptyline: Amitriptyline is a dibenzo cycloheptadiene tricyclic antidepressant. I t increases synaptic concentration of serotonin and/or norepinephrine in the CNS by blocking the neuronal reuptake o f norepinephrine and serotonin. Amitriptyline is metabolized to nortriptyline which inhibits the reuptake of norepinephrine and serotonin almost equally. Amitriptyline inhibits the membrane pump mechanism responsible for uptake of norepinephrine and serotonin in adrenergic and serotonergic neurons. Pharmacologically this action may potentiate o r prolong neuronal activity since reuptake of these biogenic amines is important physiologically in terminating transmitting activity. This interference with the reuptake of norepinephrine and/or serotonin is believed by some to underlie the antidepressant activity of amitriptyline.

 Indication:

• Neuropathic pain (pain from nerve damage)
• Diabetic nerve pain (painful diabetic neuropathy)
• Postherpetic neuralgia (pain after shingles)
• Chronic nerve pain from spinal cord injury or other causes
• May assist in fibromyalgia management and improve sleep quality for chronic pain patients.
• They are commonly prescribed for chronic pain syndromes, especially when conventional analgesics fail or for conditions with both positive and negative neurological symptoms.​

Clinical Advantages

1. Gabapentin demonstrates good efficacy in neuropathic pain conditions, with pooled clinical trial analyses showing significant reductions in pain intensity. The number needed to treat (NNT) for substantial relief ranges from approximately 6 to 8 depending on condition, and its safety profile is favourable, with a high number needed to harm (NNH).​
2. Amitriptyline is recommended as a first-line therapy for pain associated with diabetic neuropathy by major international pain societies. NNT for 50% pain relief is around 1.3, indicating high effectiveness.​

Both agents offer versatility for oral administration and can be used either as monotherapy or in combination for enhanced pain control, with dosing individualized for clinical response and tolerability.​

Gabapentin

* Binding Target: High-affinity binding to the α2δ subunit of voltage-gated calcium channels.

* Functional Role: Modulates calcium influx, indirectly influencing neurotransmitter release.

* Note: Despite structural similarity to GABA, it does not interact with GABA receptors or metabolism.

Nortriptyline

* Primary Action: Inhibits reuptake of norepinephrine (NE) and serotonin (5HT).

* Effect on Pain: Enhances descending inhibitory pain pathways in the spinal cord.

* Chemical Identity: A metabolite of amitriptyline; classified as a tricyclic antidepressant (TCA).

Indications:

* Primary Use: Management of neuropathic pain.

* Examples of Conditions:• Diabetic Peripheral Neuropathy (DPN)

* Postherpetic Neuralgia

* Cancer-related neuropathic pain

* HIV-associated neuropathy

* Radiculopathy, stroke, spinal cord injury

Clinical Advantages:

• Superior pain relief versus monotherapy, showing up to 18% better reduction in pain scores with combination therapy.
• Improved mood and reduction of depression and anxiety symptoms in chronic pain patients.
• Enhanced sleep quality, daily functioning, and overall quality of life.
• The side effect profile does not worsen compared to each drug alone, and most side effects (like sleepiness, dizziness, weight gain, dry mouth) are mild and transient.
• Expanded utility for patients unresponsive to single agents, especially in resistant neuropathic pain.

This combination is often preferred when neuropathic pain is accompanied by sleep disturbance or mood alterations, leveraging both analgesic and antidepressant effects for comprehensive symptom management.

QUBICRON is indicated for

• Neurovascular recovery: post-stroke, cognitive decline, vascular dementia
• Migraine prophylaxis: mitochondrial support and vascular modulation
• Metabolic fatigue: chronic stress, low stamina, mitochondrial dysfunction
• Cardiovascular support: heart failure, hypertension, endothelial dysfunction

Mechanism of Action:

* CoQ10: Enhances mitochondrial ATP production and antioxidant defense

* Omega-3: Reduces neuroinflammation and improves lipid profile

* L-Arginine: Boosts nitric oxide for vascular dilation and perfusion

* L-Carnitine: Facilitates fatty acid transport for cellular energy

* Selenium: Scavenges free radicals and supports immune-neural balance

Clinical Advantages:

* Improves cardiac output, vascular tone, and cerebral perfusion

* Reduces migraine frequency through mitochondrial and endothelial support

* Enhances cognitive clarity and neuroprotection

* Synergistic action for energy restoration and vascular health

* Safe and well-tolerated in cardiometabolic, migraine, and neurovascular conditions

QUBICRON —Protect your Brain. Prevent the migraine. Power your heart.

Indications:

• Partial-onset seizures – from 1 month of age
• Myoclonic seizures – in juvenile myoclonic epilepsy (≥12 yrs)
• Primary generalized tonic-clonic seizures – in idiopathic generalized epilepsy (≥6 yrs)
• Monotherapy – for partial-onset seizures in adults & adolescents (≥16 yrs)
• Off-label uses: Status epilepticus, seizure prophylaxis (SAH/TBI), neurosurgery, palliative care

Mechanism of Action:

• Selectively binds SV2A → stabilizes neurotransmitter release
• Modulates vesicle fusion & exocytosis → prevents abnormal neuronal firing
• Influences Ca²⁺ channels, GABA & AMPA pathways
• Provides neuroprotective, anti-inflammatory & antioxidant benefits

Clinical Advantages:

Broad-spectrum seizure control

Minimal drug interactions

Excellent tolerability & safety profile

Suitable for long-term therapy

Note: To be used only under the guidance of a registered medical practitioner.

LEVICRON — Trusted Protection for Every Seizure Type

Pregabalin: Pregabalin binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. In animal models of nerve damage, pregabalin has been shown to reduce calcium-dependent release of pro-nociceptive neurotransmitters i n the spinal cord, possibly by disrupting alpha2-delta containing-calcium channel trafficking and/or reducing calcium currents. Evidence from other animal models of nerve damage and persistent pain suggest the anti-nociceptive activities of pregabalin may also b e mediated through interactions with descending noradrenergic and serotonergic pathways originating from the brainstem that modulate pain transmission in the spinal cord.

Nortriptyline: Nortriptyline, a tricyclic antidepressant, inhibits the reuptake of norepinephrine and serotonin, increasing their synaptic concentrations and modulating pain pathways. It is the active metabolite of amitriptyline and enhances analgesic effects by prolonging the action of these neurotransmitters.

Indication:

• Neuropathic pain management, including pain caused by nerve damage or neuropathy.
• Diabetic peripheral neuropathy, a common cause of chronic nerve pain in diabetes patients.
• Postherpetic neuralgia, pain following shingles infection.
• Sciatic nerve pain and radiculopathy.
• Fibromyalgia, to help reduce widespread muscle pain and discomfort.
• Chronic neuropathic pain conditions unresponsive to single-agent therapy.
• May also be used adjunctively for certain epilepsy cases and generalized anxiety disorder, though primary use is neuropathic pain relief.

This combination is effective due to Pregabalin’s modulation of calcium channels reducing nerve excitability, and Nortriptyline’s inhibition of serotonin and norepinephrine reuptake increasing pain signal inhibition at the CNS level. It is well-tolerated and commonly prescribed for these indications

 Clinical Advantages

• Pregabalin provides effective pain relief with a well-characterized safety profile and is recommended as a first-line treatment for neuropathic pain.
• Nortriptyline adds antidepressant properties that address neuropathic pain-associated mood disorders, improving overall patient quality of life.
• Combining these agents allows lower doses of each, potentially reducing side effects while achieving additive or synergistic analgesic effects.
• Clinical evidence supports their use in combination therapy for refractory neuropathic pain to improve pain control and functional outcomes.

This combination is commonly utilized in clinical practice for challenging neuropathic pain cases due to its complementary pharmacology and clinical benefits

Pregabalin

1. Pregabalin binds to the alpha-2-delta () subunit of voltage-gated calcium channels in the central nervous system.
2. This binding reduces calcium influx into nerve terminals, which decreases the release of excitatory neurotransmitters such as glutamate, norepinephrine, serotonin, substance P, and others.
3. By reducing neurotransmitter release, pregabalin lowers neuronal excitability and alleviates neuropathic pain and seizures.
4. Although structurally related to GABA, pregabalin does not act on GABA receptors directly, nor does it block calcium channels like traditional calcium channel blockers.

Pregacell is indicated for:

• Neuropathic pain management, including pain caused by nerve damage or neuropathy.
• Neuropathic pain associated with diabetic peripheral neuropathy (DPN)
• Postherpetic neuralgia (PHN)
• Adjunctive therapy for adult patients with partial onset seizures
• Fibromyalgia
• Neuropathic pain associated with spinal cord injury